AC Immune (ACIU) EBITDA (2015 - 2026)

AC Immune (ACIU) has reported EBITDA for 12 consecutive years, with -$18.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA rose 12.35% year-over-year to -$18.9 million; the TTM figure through Mar 2026 stood at -$80.5 million (down 39.83% YoY), while the FY2025 annual figure was -$83.6 million, down 39.83% from the prior year.
• EBITDA fell to -$18.9 million in Q1 2026 per ACIU's latest filing, from -$18.0 million in the prior quarter.
• Across five years, EBITDA topped out at $8.4 million in Q3 2024 and bottomed at -$23.4 million in Q2 2025.
• Historically, EBITDA has averaged -$17.3 million across 5 years, with a median of -$19.4 million in 2022.
• On a YoY basis, EBITDA climbed as much as 147.92% in 2024 and fell as far as 432.39% in 2024.
• AC Immune's EBITDA stood at -$19.4 million in 2022, then soared by 79.43% to -$4.0 million in 2023, then tumbled by 432.39% to -$21.3 million in 2024, then climbed by 15.26% to -$18.0 million in 2025, then dropped by 4.86% to -$18.9 million in 2026.
• Business Quant data shows ACIU's EBITDA at -$18.9 million in Q1 2026, -$18.0 million in Q4 2025, and -$20.2 million in Q3 2025.